破发股荣昌生物跌6.92% 正拟不超20亿定增IPO募26亿

Core Viewpoint - Rongchang Biologics (688331.SH) has experienced a significant decline in stock price, closing at 46.28 yuan with a drop of 6.92%, indicating a state of breaking the issue [1] Group 1: Company Overview - Rongchang Biologics was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 31, 2022, with an initial offering price of 48.00 yuan per share and a total issuance of 54.4263 million shares [2] - The total funds raised from the initial public offering amounted to 2.612 billion yuan, with a net amount of 2.506 billion yuan after expenses [2] Group 2: Financial Performance - The company reported net profits attributable to shareholders of -999.9 million yuan in 2022, -1.511 billion yuan in 2023, and -1.468 billion yuan in 2024 [3] - The revenue for 2024 was approximately 1.717 billion yuan, reflecting a year-on-year increase of 58.54% compared to 2023 [4] - The net cash flow from operating activities was -1.114 billion yuan in 2024, showing a decrease from -1.503 billion yuan in 2023 [4] Group 3: Future Plans - Rongchang Biologics plans to raise up to 1.952 billion yuan through a specific issuance of A-shares, with the net proceeds intended for new drug research and development projects [3]